Ebselen

Sound Pharmaceuticals' Phase 3 trial of SPI-1005 met co-primary endpoints, showing significant improvements in hearing loss and speech discrimination for Meniere's disease, with no FDA-approved therapies currently available. The trial results demonstrated higher rates of improvement in low-frequency hearing loss and speech discrimination compared to placebo, with continued improvements during the open-label extension. Full trial data will be presented at the 2025 Association for Research in Otolaryngology Midwinter Meeting.